Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION In a biologics company planning a biosimilar pathway, a payer demanding RWE the protocol cannot generate put 505(b)(2) literature-to-product bridge table in play. Clinical-development physician should decide whether to drop a secondary endpoint that will dominate the AdCom without filling gaps 505(b)(2) literature-to-product bridge table does not contain.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. 505(b)(2) literature-to-product bridge table reads as Proceed under protocol once a payer demanding RWE the protocol cannot generate is lined up to the same Pharma & Life Sciences population. 2. 505(b)(2) literature-to-product bridge table is closer to Pause the pathway after a payer demanding RWE the protocol cannot generate; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in 505(b)(2) literature-to-product bridge table for clinical-development physician in a biologics company planning a biosimilar pathway. 4. 505(b)(2) literature-to-product bridge table is missing the fact clinical-development physician needs after a payer demanding RWE the protocol cannot generate; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 2. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a payer demanding RWE the protocol cannot generate and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a payer demanding RWE the protocol cannot generate, then the two facts that force it, then the Monday action for clinical-development physician in a biologics company planning a biosimilar pathway.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for clinical-development physician - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Owner and next date for clinical-development physician in a biologics company planning a biosimilar pathway - What changes to drop a secondary if a payer demanding RWE the protocol cannot generate is later withdrawn